Discontinuation due to adverse reactions was 4.5% (naïve patients) and 9% (experienced patients) over a 48 week period.
Olulisemateks viirusvastase toimega metaboliitideks on 4- oksü - ja 4- hüdroksü- metaboliitide epimeeripaarid.